RecruitingPhase 2NCT05575505

Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.

Sponsor

Tanta University

Enrollment

44 participants

Start Date

Feb 2, 2023

Study Type

INTERVENTIONAL

Conditions

Inflammatory Bowel Diseases

Summary

Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa; however, the exact underlying mechanisms of UC remain poorly understood. Also, it is associated with high risk of colon cancer, so there is a continuous need for introducing new therapies that decrease progression, and hence better outcomes

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether pentoxifylline — a drug that improves blood flow and reduces inflammation — can help people with ulcerative colitis (UC) when added to their existing treatment. UC is a chronic inflammatory bowel condition that causes sores in the large intestine. **You may be eligible if...** - You are 18 or older - You have ulcerative colitis (not severe) - You have a negative pregnancy test and use effective contraception (if applicable) **You may NOT be eligible if...** - You are breastfeeding - You have significant liver or kidney problems - You have colorectal cancer - You have severe ulcerative colitis - You are taking steroids, immunosuppressants, or biologic therapies - You have an alcohol or drug addiction Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.